EONS15 Cancer Nursing Considerations for comprehensive care in CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy offers options for paediatric and adult patients with cancer, but it comes with a unique set of side effects that can range from mild to life threatening. As forefront healthcare professionals, cancer nurses are often the first to identify signs and symptoms of adverse events and acute changes in patients’ physical and psychosocial status. Understanding what to assess and monitor for can improve patients’ outcomes and help the treatment team deliver safe, effective interdisciplinary care.

Reasons to participate:

1. To obtain an overview of operational approaches to CAR T-cell therapy program development and implementation for cancer nurses in oncology and hematology.

2. To further your understanding of best patient education, support and therapy management regardless of location and type of program that provides CAR-T therapy

3. To better understand the operational approaches to CAR T-cell therapy program development, cancer nurse education and training considerations essential for best patient outcomes.

Register for EONS15 here: http://bitly.ws/pXWr

Join the conversation and stay tuned using the hashtags #EONS15 #ESMO22 and #EONS15CarTcell.

Supported by Bristol Myers Squibb.